Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $387.16M
Last updated: Nov 17, 2026 at 11:05 AM ET
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Forecast
Analysts expect Contineum Therapeutics, Inc. Class A Common Stock (CTNM) to earn -$1.78 per share in the fiscal year ending Dec 31, 2026. Of 8 analysts, 6 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 12.5% |
| Buy | 5 | 62.5% |
| Hold | 2 | 25.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$1.78
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$2.05
- EPS consensus
- Next report
- Mar 3, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.78 | -$1.83 to -$1.72 | 7 |
| Dec 31, 2027 | -$2.05 | -$2.49 to -$1.64 | 7 |
Quarterly Estimates
The EPS consensus rises from -$0.50 for the quarter ending Dec 31, 2026 to -$0.47 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.50 | -$0.54 to -$0.35 | 10 |
| Mar 31, 2027 | -$0.47 | -$0.54 to -$0.39 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 6 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 4 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.56.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.78 | -$1.70 | -$1.71 | -$1.56 | -$1.56 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.05 | -$1.93 | -$1.92 | -$1.80 | -$1.82 | N/A |
| Quarter ending Mar 31, 2027 | -$0.47 | -$0.43 | -$0.45 | -$0.46 | -$0.46 | N/A |
Frequently Asked Questions About CTNM
What is the CTNM stock forecast?
Consensus analyst estimates put Contineum Therapeutics, Inc. Class A Common Stock's EPS at -$1.78 for the fiscal year ending Dec 31, 2026. The consensus rating from 8 analysts is Buy.
How do analysts rate CTNM stock?
Of 8 analysts covering Contineum Therapeutics, Inc. Class A Common Stock, 1 rates it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CTNM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.78, with estimates from -$1.83 to -$1.72 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.05, with estimates from -$2.49 to -$1.64 from 7 analysts.
How many analysts cover CTNM?
8 analysts rate Contineum Therapeutics, Inc. Class A Common Stock stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CTNM pages: Overview, Earnings, Forecast, Financials, Competitors